Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
...alised preclinical efficacy testing primarily for drug development companies on a 'fee for service' basis. This division on a standalone basis is cash generative and profitable with a seven-year track record of providing testing services to over 72 international company clients primarily in Europe and the Unite...EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme
...cialised preclinical efficacy testing primarily for drug development companies on a fee for service basis. This division on a standalone basis is cash generative and profitable with a five-year track record of providing testing services to over 72 international company clients primarily in Europe and the United...UW stem-cell team led by James Thomson gets $1.25M private grant
...s differentiate that is, form into the different cells. The researchers want to find out how to make adult stem cells, which typically have a limited generative ability, more like embryonic cells a discovery that would directly address moral concerns about using the cells of embryos. Thomson said the restr...